NALM-6

The NALM-6 cell line originated from blood cultures collected from a 19-year-old male patient who had been diagnosed with non-T, non-B acute lymphoblastic leukemia (ALL) during a relapse. These cultures yielded 8 “leukemia” and 2 “normal-B” cell lines. Interestingly, at the time of culture, the leukemic blasts displayed a unique membrane phenotype, characterized by the presence of SmIg (lambda and mu chain immunoglobulins), Ia-like B cell associated antigen (Ia), and the common form of ALL specific antigen (cALL). This phenotype differed from the typical non-T, non-B ALL phenotype seen at the disease’s onset. Among the 8 established leukemia cell lines (designated as NALM 6-13), variations in membrane phenotype expression were evident, despite the shared cytogenetic markers (5q- and 12p+) and monoclonal SmIg (lambda, mu). These observations suggest the potential for limited intra-clonal differentiation within the leukemia clone.

Why choose NALM-6 from AcceGen?

The NALM-6 cell line from AcceGen is characterized by its high viability and exceptional quality, maintained through stringent quality control measures. These cells are consistently monitored for sterility, ensuring the absence of bacteria and fungi, and confirmed to be negative for mycoplasma using PCR-based assays. Furthermore, they have been rigorously tested and found to be free of human pathogens such as EBV, HBV, HCV, HHV-8, HIV-1, HIV-2, HTLV-1/2, MLV, and SMRV, guaranteeing their suitability for diverse research applications.